Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Published Online: 2021-02-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Alexander L Gintsburg•Alexander S Semikhin•Alina S Dzharullaeva•Alina S Erokhova•Amir I Tukhvatulin•Andrei G Botikov•Anna V Kovyrshina•Boris S Naroditsky•Daria A Egorova•Daria M Grousova•Daria V Voronina•Denis I Zrelkin•Denis Y Logunov•Dmitry N Shcherbinin•Dmitry V Shcheblyakov•Elena A Smolyarchuk•Elizaveta A Tokarskaya•Fatima M Izhaeva•Ilias B Esmagambetov•Inna V Dolzhikova•Irina A Favorskaya•Maksim M Shmarov•Nadezhda L Lubenets•Natalia A Nikitenko•Olga Popova•Olga V Zubkova•Sergei V Borisevich•Sergey K Zyryanov•Tatiana A Ozharovskaya•Vladimir A Gushchin•Yana V Simakova
